Green tea leaf extract
Veregen is a herbal medicinal product for cutaneous use only.
The active substance is green tea leaf extract. Veregen is used to treat genital warts (Condylomata acuminata) on the surface of the genital and anal areas. Veregen is used in adults with normal immune system function.
If after 4-6 weeks there is no improvement or the patient feels worse, they should consult a doctor.
Before starting to use Veregen, the patient should discuss it with their doctor.
Veregen is not recommended for use in children and adolescents under 18 years of age.
The patient should tell their doctor or pharmacist about all medicines they are taking, have recently taken, or plan to take, or if they have recently undergone other treatments for genital warts or anal area. Veregen should not be used with other treatments in the area of the warts. Veregen should not be used if the skin has not healed after other treatments.
No interactions with food and drink.
As a precaution, to avoid interactions or side effects, Veregen should not be used at the same time as dietary supplements containing large amounts of green tea leaf extract.
If the patient is pregnant or breastfeeding, or thinks they may be pregnant or plans to have a child, they should consult a doctor before using this medicine.
Pregnancy
There are no data or only limited data on the use of Veregen in pregnant women. Animal studies have shown a harmful effect on reproduction.
Therefore, for safety reasons, Veregen should be avoided during pregnancy, even though exposure to galusan epigallocatechin (the main component of green tea) after application to the skin appears to be small (see section "3. How to use Veregen").
Breastfeeding
It is not known whether Veregen or its metabolites pass into human milk. Therefore, it is not known whether there is a risk to the breastfed child. The risk to the breastfed child cannot be excluded.
However, after application to the skin in the mother, the risk of side effects in the breastfed child appears to be small.
Fertility
There is no evidence to suggest that Veregen affects fertility when used as recommended by the doctor.
No studies have been conducted on the effect of Veregen on the ability to drive and use machines. However, it is unlikely to affect the ability to drive and use machines.
Veregen contains, in addition to other ingredients, large amounts of isopropyl myristate, which may cause skin irritation and allergic reactions, and propylene glycol monopalmitostearate, which may cause skin irritation.
This medicine should always be used as directed by the doctor. In case of doubts, consult a doctor or pharmacist.
The recommended dose is a maximum of 0.5 cm of ointment (corresponding to 250 mg) for all warts together, applied three times a day (morning, noon, and evening).
Use in children and adolescents(under 18 years of age)
Veregen is not approved for use in children and adolescents under 18 years of age.
Data on the use of Veregen in the elderly are limited.
Veregen should not be used in case of liver function disorders (e.g. if there is abnormal fluid accumulation in the abdomen, yellowing of the skin due to liver function disorders).
More severe local reactions may occur (see sections "2. Important information before using Veregen" and "4. Possible side effects").
Wash off excess ointment with mild soap and water.
In case of accidental ingestion of the ointment, consult a doctor.
Continue with the next dose at the usual time. Do not use a double dose to make up for a missed dose.
Treatment of warts may not be successful.
In case of any further doubts about using this medicine, consult a doctor or pharmacist.
Like all medicines, Veregen can cause side effects, although not everybody gets them.
Most side effects of Veregen are due to local effects on the skin and occur in the treated wart area or around it. Many patients experience redness, itching, irritation, pain, or swelling. Mild reactions can be expected, which should subside after the first few weeks of treatment. However, if the severity of local skin reactions has a negative impact on the patient's daily activities or if blisters occur, consult a doctor. It may be necessary to discontinue treatment.
Treatment can be resumed after the skin reaction has subsided. In case of local reaction, including blisters, consult a doctor.
In case of severe local reactions causing unacceptable discomfort, e.g. local inflammation/infection, ulcers, lymph node enlargement, or any other severe reaction (e.g. foreskin or urethral narrowing, difficulty urinating, or severe pain), discontinue treatment, wash off the ointment with warm water and mild soap, and consult a doctor immediately.
The following classification has been used for the frequency of side effects:
Very common | may occur in more than 1 in 10 people |
Common | may occur in up to 1 in 10 people |
Uncommon | may occur in up to 1 in 100 people |
Side effects observed only with the use of a higher-strength ointment (Veregen 150 mg/g):
If the patient experiences any side effects, including any side effects not listed in this leaflet, they should tell their doctor or pharmacist. Side effects can be reported directly to the Department of Drug Safety, Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181 C, 02-222 Warsaw, Tel.: +48 22 49 21 301, Fax: +48 22 49 21 309, Website: https://smz.ezdrowie.gov.pl
Side effects can also be reported to the marketing authorization holder.
Reporting side effects will help to gather more information on the safety of this medicine.
The medicine should be stored out of sight and reach of children.
Do not store above 25°C.
Use within 6 weeks of first opening the tube.
Do not use this medicine after the expiry date stated on the tube and carton after "Expiry date". The expiry date refers to the last day of that month.
Medicines should not be disposed of via wastewater or household waste. The patient should ask their pharmacist how to dispose of medicines no longer required. This will help protect the environment.
The active substance of Veregen is green tea leaf extract. 1 g of ointment contains 100 mg of extract (in the form of a dry extract, purified) from Camellia sinensis(L.) O. Kuntze, folium (green tea leaves) (24-56:1), corresponding to: 55-72 mg of (-)-galusan epigallocatechin.
First extraction solvent: water
Other ingredients are:
white soft paraffin (contains all-rac-α-tocopherol),
white wax,
isopropyl myristate,
oleyl alcohol,
propylene glycol monopalmitostearate.
Veregen is a brown, smooth ointment, free of grainy particles, supplied in tubes of two sizes: 15 g and 30 g.
ORNYX OÜ
Ida-Viru maakond
Jõhvi vald, Edise küla
Aiandi keskus 7, 41558
Estonia
C.P.M. ContractPharma GmbH
Frühlingsstraße 7
83620 Feldkirchen-Westerham
Germany
Austria:
Veregen 10% Salbe
Belgium:
Veregen pommade
Bulgaria:
Вереген 10% маз
Croatia:
Veregen 100 mg/g mast
Cyprus:
Veregreen 10% Αλοιφή
Estonia:
Veregen
France:
VEREGEN 10%, pommade
Greece:
Veregreen 10% Αλοιφή
Spain
Veregen 100 mg/g pomada
Netherlands:
Veregen 10%, zalf
Ireland:
Catephen 10 % ointment
Lithuania:
Veregen 100 mg/g tepalas
Luxembourg:
Veregen 10 %
Latvia:
Veregen 100 mg/g ziede
Germany:
Veregen 10% Salbe
Poland:
Veregen
Portugal:
Veregen
Czech Republic:
Veregen
Slovakia:
Veregen 100 mg/g masť
Romania:
Veregen 100 mg/g unguent
Slovenia:
Veregen 100 mg/g mazilo
Hungary:
Veregen 10% kenőcs
United Kingdom (Northern Ireland):
Catephen 10 % ointment
Italy:
Veregen
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.